Sandra K. Althouse

2.4k total citations
105 papers, 1.5k citations indexed

About

Sandra K. Althouse is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sandra K. Althouse has authored 105 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 39 papers in Surgery. Recurrent topics in Sandra K. Althouse's work include Testicular diseases and treatments (30 papers), Lung Cancer Treatments and Mutations (19 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Sandra K. Althouse is often cited by papers focused on Testicular diseases and treatments (30 papers), Lung Cancer Treatments and Mutations (19 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Sandra K. Althouse collaborates with scholars based in United States, Canada and United Kingdom. Sandra K. Althouse's co-authors include Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra, Susan M. Perkins, Costantine Albany, Higinia R. Cárdenes, Edward M. Mannina, Mary A. Maluccio, David J. Vaughn and Rafat Abonour and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Sandra K. Althouse

95 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra K. Althouse United States 20 516 500 472 352 212 105 1.5k
Yee‐Min Jen Taiwan 24 570 1.1× 540 1.1× 366 0.8× 520 1.5× 158 0.7× 70 1.9k
Philip Wong Canada 20 253 0.5× 360 0.7× 433 0.9× 258 0.7× 143 0.7× 71 1.4k
Antonio Febbraro Italy 18 253 0.5× 314 0.6× 649 1.4× 249 0.7× 241 1.1× 56 1.2k
Jae Myoung Noh South Korea 21 371 0.7× 602 1.2× 557 1.2× 139 0.4× 197 0.9× 112 1.5k
Jeroen Hagendoorn Netherlands 23 882 1.7× 363 0.7× 1.1k 2.4× 413 1.2× 176 0.8× 95 1.9k
Minzhi Xing United States 24 494 1.0× 512 1.0× 320 0.7× 434 1.2× 104 0.5× 87 1.7k
M.A. Lentz Belgium 19 389 0.8× 690 1.4× 1.0k 2.1× 163 0.5× 155 0.7× 37 1.9k
Re G Italy 20 295 0.6× 576 1.2× 823 1.7× 513 1.5× 169 0.8× 96 1.6k
Khaldoun Almhanna United States 27 1.2k 2.2× 1.1k 2.3× 982 2.1× 596 1.7× 332 1.6× 168 2.5k
Rakesh Gaur United States 17 215 0.4× 336 0.7× 901 1.9× 277 0.8× 432 2.0× 39 1.6k

Countries citing papers authored by Sandra K. Althouse

Since Specialization
Citations

This map shows the geographic impact of Sandra K. Althouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra K. Althouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra K. Althouse more than expected).

Fields of papers citing papers by Sandra K. Althouse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra K. Althouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra K. Althouse. The network helps show where Sandra K. Althouse may publish in the future.

Co-authorship network of co-authors of Sandra K. Althouse

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra K. Althouse. A scholar is included among the top collaborators of Sandra K. Althouse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra K. Althouse. Sandra K. Althouse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Seibert, Tara, Lei Shi, Sandra K. Althouse, et al.. (2024). Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer. Scientific Reports. 14(1). 1029–1029. 1 indexed citations
3.
Dinh, Paul C., Patrick O. Monahan, Chunkit Fung, et al.. (2024). Cognitive function in long-term testicular cancer survivors: impact of modifiable factors. JNCI Cancer Spectrum. 8(5). 2 indexed citations
4.
Weisman, Michael, Greg Andrew Durm, Misty Dawn Shields, et al.. (2024). Evaluation of Radiation Pneumonitis in a Phase 2 Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation Therapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 121(3). 720–727. 4 indexed citations
5.
Schneider, Bryan P., Sandra K. Althouse, Milan Radovich, et al.. (2023). Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors. JCO Precision Oncology. 7(7). e2200465–e2200465. 4 indexed citations
6.
Kumar, Brijesh, Guanglong Jiang, Poornima Bhat‐Nakshatri, et al.. (2023). Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent. Nature Communications. 14(1). 5683–5683. 9 indexed citations
7.
King, Jennifer, Kenneth A. Kesler, Sandra K. Althouse, et al.. (2023). Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors. Journal of Clinical Oncology. 41(23). 3939–3944. 4 indexed citations
8.
Richardson, Noah, Sandra K. Althouse, Clint Cary, et al.. (2023). Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only. Clinical Genitourinary Cancer. 21(4). 467–474. 5 indexed citations
9.
King, Jennifer, et al.. (2023). Bone metastasis in patients with germ-cell tumors: Analysis of survival outcomes and prognostic factors.. Journal of Clinical Oncology. 41(16_suppl). e17029–e17029. 1 indexed citations
10.
11.
King, Jennifer, Sandra K. Althouse, Clint Cary, et al.. (2022). Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor. The Journal of Urology. 208(3). 641–649. 1 indexed citations
12.
Radovich, Milan, Jeffrey P. Solzak, Bradley A. Hancock, et al.. (2022). Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 28(15). 3235–3241. 21 indexed citations
13.
Althouse, Sandra K., et al.. (2022). Venous Thromboembolic Events in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia. Journal of Adolescent and Young Adult Oncology. 11(6). 600–604. 1 indexed citations
14.
Althouse, Sandra K., et al.. (2022). Early Discharge of Adolescent and Young Adult Patients During Induction Chemotherapy for Newly Diagnosed Acute Lymphoblastic Leukemia: Is It Safe?. Journal of Adolescent and Young Adult Oncology. 12(2). 271–274.
15.
Saliba, Antoine N., et al.. (2021). Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?. Hematology/Oncology and Stem Cell Therapy. 15(2). 30–38. 6 indexed citations
16.
17.
Althouse, Sandra K., et al.. (2020). Hypogammaglobulinemia in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Journal of Adolescent and Young Adult Oncology. 9(6). 687–692. 3 indexed citations
18.
Fung, Chunkit, Howard D. Sesso, AnnaLynn M. Williams, et al.. (2017). Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. Publisher. 1 indexed citations
19.
Suvannasankha, Attaya, Rafat Abonour, Sherif S. Farag, et al.. (2017). Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma. Blood. 130. 1826–1826. 4 indexed citations
20.
Sahu, Ravi P., Kathleen A. Harrison, Matheus Ferracini, et al.. (2014). Chemotherapeutic Agents Subvert Tumor Immunity by Generating Agonists of Platelet-Activating Factor. Cancer Research. 74(23). 7069–7078. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yee‐Min Jen Breakdown of academic impact, for papers by Philip Wong Breakdown of academic impact, for papers by Antonio Febbraro Breakdown of academic impact, for papers by Jae Myoung Noh Breakdown of academic impact, for papers by Jeroen Hagendoorn Breakdown of academic impact, for papers by Minzhi Xing Breakdown of academic impact, for papers by M.A. Lentz Breakdown of academic impact, for papers by Re G Breakdown of academic impact, for papers by Khaldoun Almhanna Breakdown of academic impact, for papers by Rakesh Gaur
Rankless by CCL
2026